Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial

Autor: Hiroshi Koike, Hiroshi Urakawa, Kunihiro Ikuta, Kan Ito, Yuichi Ando, Tomohisa Sakai, Yoshihiro Nishida, Ryo Emoto, Shigeyuki Matsui, Shunsuke Hamada
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Cancer Research
desmoid
medicine.medical_treatment
Kaplan-Meier Estimate
Corrections
Gastroenterology
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Child
Univariate analysis
General Medicine
Middle Aged
Prognosis
Vinblastine
Fibromatosis
Aggressive
Treatment Outcome
Oncology
biweekly
Child
Preschool
030220 oncology & carcinogenesis
Female
Original Article
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Drug Administration Schedule
methotrexate
Young Adult
03 medical and health sciences
Clinical Research
Internal medicine
vinblastine
medicine
Humans
Adverse effect
Aged
Neoplasm Staging
Proportional Hazards Models
Chemotherapy
business.industry
clinical benefit rate
Original Articles
Discontinuation
Clinical trial
Regimen
030104 developmental biology
Methotrexate
business
Follow-Up Studies
Zdroj: Cancer Science
Cancer Sci
ISSN: 1349-7006
1347-9032
Popis: Low‐dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid‐type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution. Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m2) + VBL (6 mg/m2). Efficacy, progression‐free survival (PFS), and correlating factors were analyzed. Adverse events (AEs) were recorded. In total, 38 patients received low‐dose MTX + VBL therapy, and its efficacy was assessed in 37 of them. Nineteen (51%) patients showed partial response (PR). Clinical benefit rate was 95%. PFS at 5 y was 80.8%. In PR cases, median time to response was 10 mo. Longer duration of therapy was significantly associated with the response of PR (P = .007) by univariate analysis. There was no clear association between various clinicopathological factors, including tumor size, location, catenin beta‐1 (CTNNB1) mutation status with effect. Only 3 AEs of grade 3/4 were observed. Tumor regrowth after MTX + VBL discontinuation was observed in 5 (20%) of 25 patients. Biweekly administration of MTX + VBL chemotherapy was well tolerated compared with weekly administration, and its efficacy was anticipated in DF patents, although the time needed to achieve a response may be relatively long. The treatment interval should be determined taking into account both the condition of the tumor and the patient's preference.
Biweekly administration of MTX + VBL chemotherapy for desmoid patients was well tolerated compared with weekly administration, and its efficacy was similar. The time needed to achieve a response may be relatively long with a biweekly regimen.
Databáze: OpenAIRE
Externí odkaz: